Confidential listing · Assam · Building, plant and licences · Leasehold land
The short answer
An operating GMP pharmaceutical formulation unit in Guwahati, Assam is offered for sale at an asking price of INR 15 crore. The price covers the building, all plant and machinery and the installed infrastructure, with the manufacturing licences included. It does not include land: the plot of about 30,500 sq ft is held on a private lease, the owner built the 16,000 sq ft of built-up area on it, and no land title passes in this sale. Both areas are seller-declared.
The unit holds State manufacturing licences in Form 25 and Form 28, issued in March 2017 by the Drugs Control Organization, Assam, with licence retention fees deposited to 27 March 2027. A State GMP certificate dated 8 January 2026 records that the firm follows revised Schedule M for capsules, oral liquids, ointments and creams. The seller declares average annual turnover of about INR 22 crore over the last three years, declared capacity of 7,20,000 capsules per 8-hour shift, a WHO-GMP renewal in process, and a lease renewal option and a licence-ownership change option that the seller says will be available.
The three questions that decide this deal: what the buyer actually gets on the land (the seller says a renewal option will be available, but the term and the clause are not declared); how the licences move when the plant changes hands (the seller says ownership can be changed, which needs a named mechanism); and what the certificates do and do not prove, given that the State GMP certificate expires on 7 January 2027 and the WHO-GMP renewal is still in process. All three are addressed on this page.
Listing prepared by Laafon Galaxy Pharmaceuticals · Published 17 November 2026
- Asking priceINR 15 Cr
- LocationGuwahati, Assam
- LandPrivate lease · no title
- Plot size30,500 sq ft (declared)
- Built-up area16,000 sq ft (declared)
- BuildingOwner-built · included
- Lease renewalOption declared by seller
- LicencesForm 25 & 28 · included
- Licence ownershipChange option declared
- State GMP certificateValid to 7 Jan 2027
- WHO-GMPUnder renewal (declared)
- Avg turnover, 3 yearsAbout INR 22 Cr (declared)
- SectionsCapsules · liquids · ointments, tubes & lotion
How to read this page. Verification level: document reviewed, 17 November 2026. Laafon Galaxy has seen copies of the State licence retention certificate, the Form 25 and Form 28 licence forms (names and numbers are withheld from this page) and the State GMP certificate. It has not confirmed any of them with the Drugs Control Organization, Assam, has not inspected the site and has not measured the premises. The equipment list, rated and monthly capacities, plot and built-up areas, turnover, lease position, WHO-GMP renewal status and price are declared by the seller. The photographs corroborate part of the equipment list; they do not establish condition, qualification status or achieved output. Treat this page as the basis for a site visit and a document check, not a substitute for either.
The facility
Photographs supplied by the seller. Select any image to enlarge it.
-
Capsule fillingCapsule filler with polishing and sorting unit, sifter and powder hopper. -
Blister packingAlu-alu blister machine with guarded enclosure and touch-screen control. -
Oral liquid sectionSyrup manufacturing tank, storage tank and sugar melting tank, with asset tags. -
Ointment and cream fillingTube filling and sealing machine with guarded filling station. -
Quality control laboratoryBacteriological incubator and BOD incubator in the QC laboratory.
What the photographs evidence, and what they do not. They show named, branded production equipment in each of the three main dosage-form sections, numbered asset tags on several machines (a sign that an equipment register probably exists, so ask for it), and incubators in the quality control laboratory. They do not show air handling performance, differential pressures, water quality, calibration or qualification status, or whether the machines run to their rated speed. Those are established by qualification records and a live inspection.
What you are buying
What the INR 15 crore covers, and what it does not
| Item | Position as declared | What to confirm |
|---|---|---|
| Building | Included. Constructed by the facility owner on the leased plot. Built-up area declared at 16,000 sq ft. | Approved building plan, completion or occupancy documents and fire safety clearance. Check the 16,000 sq ft against the filed layout, and get a room-wise area statement and the floor count. |
| Plant and machinery | Included: “all machinery”. Thirteen items are declared with make and rated capacity. | Whether the laboratory instruments seen in the photographs are in the inventory, plus year of installation and qualification status of each machine. |
| Infrastructure | Included, as installed in the building. | The information received does not itemise it. Get a schedule covering air handling, water, power, compressed air and any steam source. |
| Manufacturing licences | Included: Form 25 and Form 28, held in the seller entity’s name. The seller says licence ownership can be changed. | The mechanism: purchase of the entity, or a fresh grant in the buyer’s name with seller support. Get the Licensing Authority’s position in writing. See the licence section below. |
| Land | Excluded. Plot of about 30,500 sq ft held on a private lease. No land title is transferred. The seller says a lease renewal option will be available. | Whether the existing lease is assigned to the buyer or a fresh lease is signed with the lessor, and the renewal clause: who can use it, for how long and at what rent. |
| Brands, dossiers, contracts, staff | Not stated. | Treat as open for negotiation. Do not assume any of them is included. |
Scroll the table sideways on a phone.
The lease question comes before every other question. The seller sells a building on land it does not own. What the buyer can lawfully do with that building, and for how long, is set by the lease deed and by the lessor, neither of which is party to this listing. The seller says a renewal option will be available. That stays a claim until the clause is read. Section “The lease decides what this asset is worth” below sets out what to ask.
Licences and regulatory position
The unit falls under the Drugs Control Organization, Assam, the State licensing authority, whose office on the certificates supplied is at Hengrabari, Guwahati [9]. The two licences are not interchangeable [4], and the documents supplied record the following:
| Document | What it records | Dates | Watch point |
|---|---|---|---|
| Form 25 (Rule 70) | Licence to manufacture for sale or distribution drugs other than those in Schedules C, C(1) and X. A manufacturing chemist and an analytical chemist are named as competent technical staff. | Issued March 2017 | The product permission list (“list enclosed” on the licence) decides what may be made on day one. |
| Form 28 (Rule 76) | Licence to manufacture drugs specified in Schedules C and C(1), excluding Schedule X. The same two roles are named. | Issued March 2017 | Ask which Schedule C or C(1) items are endorsed. The declared dosage forms are otherwise ordinary Form 25 scope. |
| Licence retention certificate | Retention fees deposited for both licences. The licences remain valid on that basis under G.S.R. 1337(E) of 27 October 2017 [5]. | Certificate dated 20 October 2022. Covers 28 March 2022 to 27 March 2027. | The next five-yearly retention fee falls due before 27 March 2027. A late fee applies for delay, and non-payment leaves the licence deemed cancelled [6]. |
| State GMP certificate | The firm follows GMP under revised Schedule M for capsules, oral liquid, ointment and cream. Issued on an Inspector of Drugs report, and stated to be for the limited purpose of tender or supply submissions to government organisations. | Dated 8 January 2026. Valid one year, to 7 January 2027. | It is a State certificate, not WHO-GMP. It is not permanent and needs renewal. |
| WHO-GMP | The seller declares WHO-GMP certification and says it is under renewal. No WHO-GMP certificate has been supplied to or seen by Laafon Galaxy. | Not supplied. No renewal date declared. | Ask for the current certificate with its validity and for the renewal application with its acknowledgement. Until a renewed certificate is in hand, treat WHO-GMP as unproven. |
Scroll the table sideways on a phone.
Four dates and statuses that matter
- State GMP certificate expires 7 January 2027 About seven weeks after this listing was published Ask for the renewal application and the inspection plan behind it.
- Licence retention period ends 27 March 2027 About four months after this listing was published The next five-year retention fee must be deposited before this date.
- Lease term Not declared The date that matters most The seller says a renewal option will be available. Get the registered lease deed to see its terms.
- WHO-GMP renewal In process No date declared Ask for the current certificate and the renewal application acknowledgement.
Ask at diligence: the product permission list endorsed on each licence, not just the licence copies; proof that the retention fee is paid to 27 March 2027; the Inspector of Drugs report behind the State GMP certificate; and the WHO-GMP certificate now under renewal, with its validity and the renewal application. Reconcile the issue dates and validity periods printed on the licences against the retention certificate and the GMP certificate, because the three documents were issued at different times and should agree with one another.
Declared plant and machinery
Thirteen items are declared by the seller, with make and rated output. The “Section” column is Laafon’s grouping by function, not the seller’s. Where a machine could serve two sections it is marked as inferred.
| # | Equipment | Make | Rated capacity (declared) | Section |
|---|---|---|---|---|
| 1 | Double cone blender | Amulya Industries | 400 litres | Capsules |
| 2 | Automatic capsule filling machine | Anchor Mark | 90,000 capsules/hr | Capsules |
| 3 | Alu-alu blister packing machine | Elmach | 1,20,000 capsules/hr | Capsules, packing |
| 4 | Strip packing machine | Satellite Engineers | 2,00,000 capsules/hr | Capsules, packing |
| 5 | Carton printing machine | Devikrupa | 9,600 cartons/hr | Cartoning |
| 6 | Ointment manufacturing tank | Anvay Pharma System | 1,000 litres | Ointments and creams |
| 7 | Tube filling and sealing machine | Pac Mac | 7,200 tubes/hr | Ointments and creams |
| 8 | Autocartonator | Pac Mac | 9,000 cartons/hr | Cartoning |
| 9 | Manufacturing tank, oral liquid | Maruti Pharma Machinery | 3,000 litres | Oral liquids |
| 10 | 6-head servo liquid filling machine | Maruti Pharma Machinery | 4,800 bottles/hr | Oral liquids |
| 11 | Automatic sticker labelling machine | Maruti Pharma Machinery | 7,200 bottles/hr | Oral liquids |
| 12 | Liquid filling machine | Ambalica Engineers | 3,000 bottles/hr | Lotion (external preparation), inferred |
| 13 | Sticker labelling machine | Parth Engineers | 7,200 bottles/hr | Liquids, shared or lotion |
Scroll the table sideways on a phone.
Declared manufacturing capacity
The seller declares capacity by section, per 8-hour shift and per month at full capacity.
| # | Section | Per 8 hours (declared) | Monthly, full capacity (declared) | Check against the machine rating |
|---|---|---|---|---|
| 1 | Capsule | 7,20,000 capsules | 5.40 crore capsules | Matches. 90,000 an hour x 8 = 7,20,000, the capsule filler rating. |
| 2 | External preparation (tubes) | 57,600 tubes | 50 lakh tubes | Matches. 7,200 an hour x 8 = 57,600, the tube filler rating. |
| 3 | External preparation (lotion) | 24,000 bottles | 20 lakh bottles | Matches the 3,000 an hour rating of the second liquid filler (24,000 / 8). Which filler serves lotion is Laafon’s inference. |
| 4 | Oral liquid | 38,400 bottles | 30 lakh bottles | Matches. 4,800 an hour x 8 = 38,400, the 6-head servo filler rating. |
Scroll the table sideways on a phone.
The monthly figures assume round-the-clock running. Dividing each monthly figure by its 8-hour figure gives about 75 shifts a month for capsules, 87 for tubes, 83 for lotion and 78 for oral liquids. At three shifts a day that is roughly 25 to 29 days of continuous running. Only the capsule figure fits a 25-day, three-shift month exactly. The tube, lotion and oral liquid figures sit above it, which would give 43.2 lakh, 18 lakh and 28.8 lakh. Ask for the shift pattern the unit actually runs and for monthly output from the batch records.
Rated is not achieved. The per-shift figures are nameplate ratings, which are theoretical maxima, and a line runs no faster than its slowest machine. Ask for three months of batch manufacturing records and compute achieved output per shift from them. Also ask which lines share the single autocartonator and the single carton printer, because cartoning can become the real ceiling when two sections run at once.
There is no tablet line. No compression, granulation or coating equipment appears on the declared list, and the GMP certificate names capsules, oral liquid, ointment and cream. A buyer whose portfolio is tablet-led should budget for that line and for the licence endorsement it would need. Lotion is also not named on the certificate, which lists capsule, oral liquid, ointment and cream, so confirm that it is on the product permission list.
Seen in the photographs, not on the declared list
The seller supplied more photographs than the list covers. Confirm that each item below is within “all machinery” and appears in the equipment register.
- Capsule section: a capsule polishing and sorting unit, with a sifter and powder hopper beside the filler.
- Oral liquid section: a sugar melting tank of about 2,200 litres and a 3,000 litre storage tank beside the syrup tank, and a cap sealing machine in line with the liquid filler.
- Ointment section: wax-phase and aqueous-phase vessels feeding the main manufacturing vessel.
- Quality control laboratory: a stability chamber, a bacteriological incubator, a BOD incubator, a centrifuge, a Karl Fischer autotitrator, a dissolution tester and a binocular microscope. The incubators and microscope are consistent with microbiological testing capability, but the laboratory layout and full instrument list have not been supplied.
Land and building
The land is held on a private lease and the building was constructed by the facility owner. The seller declares a plot of 30,500 sq ft (about 2,834 sq m) and a built-up area of 16,000 sq ft (about 1,486 sq m). The built-up area is about 52% of the plot area, but the number of floors and the year of construction are not declared, so that ratio is not a measure of site coverage. Ask for the approved building plan, the layout drawing filed with the licensing authority, a room-wise area statement and the floor count, then compare the areas against the published benchmarks in our Schedule M plant area requirements guide.
Utilities and support systems: not declared
The information received does not describe any utility system, and this page will not invent one. The photographs show ceiling air diffusers and return grilles, smooth wall finishes and a numbered equipment tagging scheme. That is physical fabric, not performance. Put all six items below in your first written request.
- Purified water: system design, qualification package and at least twelve months of conductivity, total organic carbon and microbial trend data. Oral liquids and ointments depend on it.
- HVAC: air handling units per section, HEPA filtration, differential pressure records and the qualification package.
- Steam: whether a boiler exists, its rating and fuel and its Boiler Inspectorate registration, or whether the process design avoids steam. A sugar melting tank and a jacketed ointment vessel normally need a heat source.
- Effluent: the treatment arrangement and the current consent to operate from the Pollution Control Board, Assam, with expiry dates.
- Power: sanctioned load and the standby generator capacity.
- Compressed air and chilled water: whether installed, and for which machines.
The lease decides what this asset is worth
Most plants listed for sale come with their land. This one does not, and that changes the valuation, the financing and the licence risk, not only the paperwork. The seller says a lease renewal option will be available. That is the right thing to have, and it is still a claim until the clause is read.
Both licences are granted for specific premises: the Form 25 and Form 28 texts license manufacture at the premises stated on the licence, and require the licence to be kept there [4]. If the lease ends, or the lessor will not deal with a new owner, the licensed premises go with it. A different site would need fresh regulatory approval, so confirm the position with the Drugs Control Organization, Assam before relying on any other plan.
A lease of immovable property for a term exceeding one year can be made only by a registered instrument [7]. Ask for the registered deed, not a summary of it, and have your lawyer read the following six points.
- Term left, and renewal. How many years remain, and the renewal clause the seller refers to: who can use it, for how long, at what rent, and whether it survives a sale or a change of control.
- Assignment. Whether the lessee may assign the lease, whether the lessor’s written consent is needed, and whether a consent fee applies.
- Change of control. If the deal is a purchase of the company, whether a change in shareholding triggers a consent right or a termination right.
- Improvements. Who owns the building at the end of the term, and whether the lessee may remove it.
- Rent and escalation. Current annual rent, the escalation clause and any arrears.
- Lessor’s cooperation for the licence. Whether the lessor will supply the documents the licensing authority asks for when the licence is amended or re-issued.
Lease-life lens
What does INR 15 crore cost per year of tenure?
Enter the years left on the lease
The result appears here. It is straight-line and undiscounted, so it is a way to think about the price, not a valuation.
Financing and valuation. A building on land you do not own is harder to value and to borrow against. Lenders usually look for land security, and a charge over a leasehold interest typically needs the lessor’s consent. Raise this with your bank before you sign, not after.
Revised Schedule M: what the January 2026 certificate tells you
The revised Schedule M was notified by the Ministry of Health and Family Welfare as G.S.R. 922(E) dated 28 December 2023 [1]. Manufacturers with annual turnover up to INR 250 crore were later given until 31 December 2025 to comply, provided they filed an upgradation plan [2]. That window has closed and no further extension is in force. In November 2025 the Drugs Controller General of India directed State and Union Territory drug controllers to begin inspections against the revised standard and to file monthly reports [3].
The State GMP certificate for this unit is dated 8 January 2026, eight days after the MSME window closed. It states that the firm follows GMP as stipulated under the revised Schedule M for capsules, oral liquid, ointment and cream, and it was issued on the report of an Inspector of Drugs.
Why that matters to a buyer. A certificate issued after the deadline, on an inspector’s report, is stronger evidence than a seller’s statement that an upgrade is planned. It is also the only third-party compliance evidence supplied with this listing.
Read it as evidence, not clearance. The certificate is a limited-purpose document issued for tender and supply submissions, it runs for one year and it expires on 7 January 2027. It does not replace the inspection that a buyer, or a fresh licence application, would face. Ask for the Inspector of Drugs report behind it, the gap assessment against the revised standard, the upgradation plan as filed, and the renewal plan. Then check the systems half of the standard, which cost people and time rather than concrete: a pharmaceutical quality system, quality risk management, product quality review, change control, qualification and validation, and supplier audits [1]. No published Assam-wide compliance count was found when this listing was prepared, so the unit’s own inspection record is the evidence that counts. The WHO-GMP renewal the seller mentions is a separate process, and no WHO-GMP certificate was supplied.
Run a first-pass readiness view against the twelve inspection focus areas on the Revised Schedule M readiness checker.
What happens to the licences when the plant changes hands
The seller states that the licences are included and that licence ownership can be changed. A manufacturing licence attaches to the licensee and to named premises, so it cannot be sold the way a machine can. Both Form 25 and Form 28 carry the same standard condition: the licensee must inform the Licensing Authority in writing of any change in the constitution of the firm, and after such a change the licence is deemed valid for a maximum of three months unless a fresh licence has been taken in the name of the firm with the changed constitution [4]. Both licences also require any change in the named competent technical staff to be reported forthwith. In practice the seller’s ownership-change option points to this change-in-constitution route, so ask the seller to name the mechanism and ask the Licensing Authority to confirm the route and its timeline in writing.
| Deal structure | What happens to Form 25 / 28 | Practical consequence |
|---|---|---|
| Purchase of the company that holds the licences | The licensee entity is unchanged, so the licences continue in the same name | The fastest route to production, and the most natural fit for an offer described as building, machinery and licences. Agree the written intimation to the Licensing Authority before completion, because a change in constitution starts the three-month clock. You inherit every historical liability of the entity. |
| Purchase of assets, with the seller’s support for a fresh licence | The licences do not travel. A fresh licence is needed in the buyer entity’s name | Plan for a fresh application, inspection and grant, plus fresh product permissions, with no production until grant. Ask what the seller’s support actually commits it to, and who bears the risk that the grant is refused or delayed. |
| Joint venture or majority stake | May amount to a change in constitution, depending on the shareholding change | Get the Licensing Authority’s position in writing before signing. Do not rely on the seller’s assurance. |
Scroll the table sideways on a phone.
Confirm in the term sheet which of these routes “licences included” means. On this unit the difference is measured in months of lost production, and, because the land is leased, in whether the licensed premises remain available to the new licensee at all.
Which route into Assam fits you?
Buying a plant is one of four ways to manufacture in Assam, and it is not automatically the right one. Answer both rows.
1. What do you want out of Assam?
2. What can you commit?
Pick one option in each row
The verdict and the regulatory control point that governs it will appear here.
Routes referenced above: loan licence facilitation on a vetted host facility · third-party contract manufacturing · PCD franchise · all pharma plants for sale.
Buy this unit, or build one?
The honest comparison is not price against price. It is price against time to first saleable batch, and against what the price actually buys. This asking price excludes land, so compare it with the replacement cost of a building and machinery only, then add the cost of securing land on a lease or by purchase.
| Route | Capital | Time to first commercial batch | Licence position |
|---|---|---|---|
| Acquire this unit | INR 15 Cr asking, excluding land | Weeks, if structured as a purchase of the licensed entity | Existing Form 25 and 28 continue with the entity. GMP certificate needs renewal by 7 January 2027 |
| Greenfield build | See our current cost bands, plus land | 18 to 30 months including licensing | Fresh application, inspection and grant, against the revised standard from day one |
| Loan licence | Working capital only | Typically a few months | Form 25A or 28A in your name, on a host facility |
| Third-party manufacturing | Working capital only | Weeks | None. The host manufactures on its own licence |
Scroll the table sideways on a phone.
Current greenfield capital bands by plant type, and where the money actually goes, are set out in our pharma manufacturing plant cost guide for 2026. For an indicative number for your own configuration, the plant setup cost calculator takes about two minutes. Run it before you negotiate.
Location: Guwahati and the Assam pharma market
The unit is in Guwahati, Assam. The exact address, plot details and lease documents are released after a mutual NDA.
Three facts matter more than a map. First, the regulator is in the same city: the State licensing authority sits at Hengrabari, Guwahati [9], and CDSCO opened a sub-zonal office in Guwahati in 2017 [8], which shortens the loop on inspections, endorsements and queries. Second, there is outside investment interest in Assam manufacturing: in February 2026 the Assam Chief Secretary said he had reviewed a Sun Pharmaceutical proposal for a plant of over INR 500 crore in two phases, described as a proposal under review rather than a confirmed project [10]. Third, the GMP certificate was issued for government tender and supply submissions, which hints at a government-supply customer base. Ask the seller what share of the declared turnover came from tenders and what share from private customers.
The counterweight, stated plainly. Vendor depth is typically thinner in the North East than in the large Himachal and Uttarakhand pharma belts. Packaging converters, calibration and analytical service providers and experienced QA and QC staff may need to be brought in or retained at higher cost. Price inbound freight, spares lead times and hiring into your model, and test them on the site visit.
Ten questions to put to this seller
Drawn from the specific claims and the specific silences in this listing, rather than from a generic template. Our 50-point pharma plant acquisition checklist covers the rest of the diligence programme.
- Produce the registered lease deed, with remaining term, the renewal option the seller mentions, rent and escalation, assignment and change-of-control clauses, and the lessor’s written position on this sale.
- State who owns the building at the end of the lease, and produce the approved building plan, completion or occupancy documents and fire safety clearance.
- Confirm in writing what “licences included” and “licence ownership can be changed” mean: a purchase of the licensed entity, or a fresh grant in the buyer’s name. Share the licensing authority’s written position on the filing route.
- Provide the product permission list endorsed on each of Form 25 and Form 28, and say which Schedule C or C(1) items are covered by Form 28.
- Share the Inspector of Drugs report behind the 8 January 2026 GMP certificate, the revised Schedule M gap assessment, the upgradation plan as filed, the plan to renew the certificate before 7 January 2027, and the WHO-GMP certificate with its validity and the renewal application.
- Show proof that the licence retention fee is paid to 27 March 2027, and the compliance calendar for the next five-year retention.
- Supply the machine-wise equipment register with year of installation, qualification and calibration status, and confirm that the laboratory instruments in the photographs are included.
- Give three months of batch manufacturing records so achieved output per shift can be computed, and say which lines share the autocartonator and carton printer.
- Produce the purified water and HVAC qualification packages, twelve months of water trend data, the steam and effluent arrangements, and the current consent to operate from the Pollution Control Board, Assam.
- Provide three years of financial statements behind the approximately INR 22 crore average turnover, split between own brands, contract manufacturing and government tenders, and confirm which technical staff named on the licences will transfer.
Deal terms and ideal buyer
The proposed transaction is the sale of the building, all plant and machinery and the installed infrastructure of an operating unit, with its manufacturing licences, at an asking price of INR 15 crore. Land is excluded and no land title passes. Whether the existing lease is assigned or re-granted, on what terms the renewal option the seller mentions applies, and whether brands, product dossiers, contracts and key employees transfer, is open to negotiation. Detailed financials, licence copies and technical documentation are shared only after a mutual NDA and initial profile screening.
On the declared numbers, the asking price is about 0.7 times the declared average annual turnover of about INR 22 crore. Turnover is not profit and not enterprise value, so ask for earnings, not only revenue, and compare the price with the replacement cost of the building and machinery. Both numbers are seller-declared until audited accounts are reviewed.
The profile that fits best: a regional marketing or PCD company that wants captive capsule, syrup and ointment capacity in the North East instead of buying from several contract manufacturers; a company with a government-supply focus that can use a State GMP certificate for tenders; or a buyer with a functioning quality organisation that can complete the revised Schedule M programme and renew the certificate quickly. It fits poorly for a buyer who needs land title or a tablet line, and for one without in-house quality leadership. That buyer should budget for the hire before anything else.
Register interest in this Guwahati unit
Send your company name, business model, regulatory focus and intended use of the asset with your first message. That lets us screen quickly and share the right level of detail without wasting a round trip. Quote reference Pharma Plant For Sale in Guwahati, Assam in your subject line.
Darshan Singh · Promoter representative
Email: contact@laafon.com
Phone / WhatsApp: 9812446733
Frequently asked questions
The seller presents it as an operating unit, with a valid drug manufacturing licence, a valid State GMP certificate dated 8 January 2026 and average annual turnover of about INR 22 crore declared for the last three years. Current production status is not independently confirmed, so inspect recent batch manufacturing records and the equipment on the site visit rather than relying on the declaration alone.
The asking price is INR 15 crore. It covers the building constructed by the facility owner, all plant and machinery, the installed infrastructure and the manufacturing licences. It does not include land. The plot is held on a private lease and no land title is transferred. Whether the lease itself is assigned to the buyer is a point to settle in writing before any offer. The seller declares a plot of 30,500 sq ft and a built-up area of 16,000 sq ft.
The land belongs to a private lessor and the seller holds it on lease. The seller says a lease renewal option will be available, but the remaining term, the renewal clause and the ownership of the building at the end of the term have not been declared. A lease of more than one year must be made by a registered instrument, so ask for the registered deed. The licences are granted for specific premises, so lease continuity matters for the licences as well as for the building. Have a lawyer review the deed before you make an offer.
The seller states that the licences are included and that licence ownership can be changed, but a licence attaches to the licensee and to named premises, not to the building. If you buy the licensed company, the licensee entity is unchanged and the licences continue, subject to written intimation to the Licensing Authority. If you buy only the assets, you must apply for fresh licences in your own name. The Form 25 and Form 28 conditions state that after a change in the constitution of the firm, the current licence is deemed valid for a maximum of three months unless a fresh licence has been taken in the changed name.
The State GMP certificate dated 8 January 2026 names capsules, oral liquid, ointment and cream. The declared equipment list matches: capsule filling and packing, oral liquid manufacturing, filling and labelling, and ointment manufacturing and tube filling. No tablet compression or coating equipment is declared. Confirm the exact scope against the product permission list endorsed on each licence.
A State GMP certificate dated 8 January 2026 states that the firm follows GMP under the revised Schedule M for capsules, oral liquid, ointment and cream, and it was issued on an Inspector of Drugs report. It is a limited-purpose certificate for tender and supply submissions, valid for one year to 7 January 2027, so it is evidence rather than a permanent clearance. Ask for the inspector report, the gap assessment and the renewal plan.
The seller declares capacity per 8-hour shift: 7,20,000 capsules, 57,600 tubes, 24,000 lotion bottles and 38,400 oral liquid bottles. At full capacity the seller quotes 5.40 crore capsules, 50 lakh tubes, 20 lakh lotion bottles and 30 lakh oral liquid bottles a month. Each per-shift figure matches the rating of the machine behind it, but the monthly figures assume round-the-clock running. These are nameplate ratings, so achieved output is lower and should be computed from three months of batch manufacturing records.
Since G.S.R. 1337(E) of 27 October 2017, manufacturing licences remain valid perpetually if the licensee deposits a retention fee before the end of every succeeding five-year period. The retention certificate supplied covers 28 March 2022 to 27 March 2027, so the next retention fee falls due before 27 March 2027. A late fee applies for delay, and if the fee is not paid the licence is deemed cancelled. Ask for proof of payment and for the seller’s compliance calendar.
No export registrations are declared with this listing. The seller says WHO-GMP certification is under renewal, but no WHO-GMP certificate has been supplied, and the certificate seen is a State GMP certificate issued for government tender and supply submissions. A renewal in process is a status, not a certificate, so ask for the current certificate, its validity and the renewal application. A buyer wanting export markets should also budget for product registration in each destination country.
At enquiry stage you receive a high-level overview at the level of detail on this page. The exact address, lease deed, licence copies, product permission lists, financial statements, the GMP inspection report and qualification documents are released only after a mutual NDA and confirmation of genuine buying intent. Site visits follow preliminary discussion and NDA execution. Bring a quality professional and a lawyer to the first visit, not only a commercial lead, because the lease and the licence structure decide the transaction.
The seller declares a plot of 30,500 sq ft (about 2,834 sq m) and a built-up area of 16,000 sq ft (about 1,486 sq m). The land is held on a private lease and the building was constructed by the facility owner. The number of floors and the year of construction are not declared, so check both areas against the approved building plan and the layout drawing filed with the licensing authority.
Related on laafon.com
- 50-point pharma plant acquisition checklist — the full GMP due-diligence programme this page draws its ten questions from.
- Revised Schedule M readiness checker — score a unit against the twelve inspection focus areas in about two minutes.
- Schedule M plant area requirements — benchmark the floor areas before your site visit.
- Loan licence facilitation, Form 25A and 28A — manufacture in your own name on a vetted host facility.
- All pharma plants for sale — other units across India.
- Regulatory compliance consultation — if you want the GMP certificate and the lease reviewed before you make an offer.
References
- Ministry of Health and Family Welfare, Government of India. Drugs (Amendment) Rules, 2023 — revised Schedule M, Good Manufacturing Practices for pharmaceutical products. Notification G.S.R. 922(E), 28 December 2023. Gazette of India, Extraordinary, Part II, Section 3(i). Available from: notified text (PDF). Accessed November 2026.
- Ministry of Health and Family Welfare, Government of India. Extension of timeline for compliance with revised Schedule M for small and medium manufacturers with turnover up to INR 250 crore, to 31 December 2025. Notification G.S.R. 127(E), 11 February 2025. Reported in: CliniExperts regulatory update. Available from: cliniexperts.com. Accessed November 2026. Secondary source; verify against the gazette before relying on it commercially.
- Business Standard. Pharma units likely to face action for Schedule M violations: experts. 8 November 2025. Reporting a Drugs Controller General of India directive dated 7 November 2025 to State and Union Territory drug controllers to commence inspections against the revised standard and file monthly reports. Available from: business-standard.com. Accessed November 2026. Trade press; secondary source.
- Drugs and Cosmetics Rules, 1945. Form 25 (see Rule 70), licence to manufacture for sale or distribution of drugs other than those specified in Schedules C, C(1) and X; and Form 28 (see Rule 76), licence to manufacture for sale or distribution of drugs specified in Schedules C and C(1) excluding those specified in Schedule X. Licence conditions, including change in the constitution of the firm and change in competent technical staff. Specimen licence text available from: specimen Form 25 and Form 28 (PDF). Accessed November 2026. The conditions were also read on the licence copies supplied by the seller.
- Central Drugs Standard Control Organisation. G.S.R. 1337(E) dated 27.10.2017: perpetuality of licence (Drugs and Cosmetics Rules, 1945). Listed on the Central Licence Approving Authority page. Available from: cdsco.gov.in. Accessed November 2026.
- Mondaq. The Drugs and Cosmetics (11th Amendment) Rules, 2019 offers effective implementation of permanency of licenses. Describing licences that remain valid if the licensee deposits the licence retention fee every five years, and deemed cancellation on non-payment. Available from: mondaq.com. Accessed November 2026. Secondary source; confirm current fees and late-fee rates with the Drugs Control Organization, Assam.
- Transfer of Property Act, 1882, section 107: leases how made. A lease of immovable property from year to year, or for any term exceeding one year or reserving a yearly rent, can be made only by a registered instrument. Available from: advocatekhoj.com. Accessed November 2026. Not legal advice; State amendments and exceptions may apply.
- Central Drugs Standard Control Organisation. Suo moto disclosure, Sub-Zone Guwahati. Records that the CDSCO Sub-Zone, Guwahati, Assam was started in 2017. Available from: cdsco.gov.in. Accessed November 2026.
- Commissionerate of Food and Drugs Administration, Government of Assam, the State drugs control authority. Available from: fda.assam.gov.in. The Hengrabari, Guwahati office address is taken from the certificates supplied by the seller. Accessed November 2026.
- Medical Dialogues. Sun Pharma to invest Rs 500 Cr in Assam manufacturing plant, 500+ jobs expected. 7 February 2026. Reporting an Assam Chief Secretary statement on a proposal under review. Available from: medicaldialogues.in. Accessed November 2026. Trade press; confirm the current status of the proposal.
This listing is technical and commercial information for prospective buyers. It is not investment, legal, tax or medical advice, and it is not an offer or invitation to invest. Licence dates, equipment, rated and monthly capacities, plot and built-up areas, turnover, lease position, WHO-GMP renewal status and price figures are declared by the seller, and the licence and certificate copies supplied have not been confirmed with the Drugs Control Organization, Assam. Verify each against original documents and a physical inspection before committing funds. Indian statutory instruments, including Schedule M and the Drugs and Cosmetics Rules, 1945, are amended frequently and State practice varies. Confirm the current position with the Drugs Control Organization, Assam and with your own regulatory and legal advisers before acting.


